Sunscreen and Mole Counts in Children: The JAMA Pediatric Trial
Melanocytic nevi, commonly known as moles, originate in childhood and are largely caused by solar exposure. Because a high nevus density is an established risk factor for cutaneous malignant melanoma, researchers have long explored whether shielding young skin from ultraviolet radiation can influence how many moles appear over time. A landmark randomized trial published in 2000 in JAMA directly tested whether broad-spectrum sunscreen could curb nevus development in fair-skinned school-age children.
The Vancouver Trial Design and Protocol
To assess how ultraviolet protection affects mole growth, researchers launched a randomized trial running from June 1993 to May 1996 in Vancouver, British Columbia. The study enrolled 458 schoolchildren in grades 1 and 4 who were randomized in 1993. Each child underwent a comprehensive baseline body count where their nevi were enumerated at the start of the study, followed by a repeat count at the end of the trial in 1996.
The participants were divided into two distinct groups:
- The sunscreen intervention group: Parents of children randomly assigned to this arm (n=222) were provided with a supply of SPF 30 broad-spectrum sunscreen. They were instructed to apply the lotion to exposed skin sites whenever the child was expected to be outdoors in the sun for 30 minutes or more.
- The control group: Children randomly assigned to this cohort (n=236) received no sunscreen from the study administrators and were provided no instructions or advice regarding sunscreen use.
After excluding nonwhite children and accounting for individuals lost to follow-up or possessing missing information, a final cohort of 309 children remained for full statistical analysis, as detailed in the JAMA clinical trial report.
What the Trial Found: Fewer New Nevi and the Freckle Factor
The primary outcome measure was the total number of new nevi acquired over the 3 years of monitoring. When comparing the intervention group to the control arm, the researchers observed a statistically significant difference in mole acquisition. Children in the broad-spectrum sunscreen arm developed fewer nevi than their peers in the control group, recording median counts of 24 versus 28 (P=.048).
Crucially, the investigators identified a significant interaction between baseline freckling and the assigned study group. Sunscreen application proved to be much more impactful for children with freckles than for children without freckling. Mathematical modeling of the trial data suggested that freckled children allocated to the broad-spectrum sunscreen protocol would develop 30% to 40% fewer new nevi compared to freckled children who were assigned to the control group.
What the Findings Do Not Prove
While the trial demonstrated that broad-spectrum sunscreen can attenuate mole formation, it is critical not to overstate the scope of this single investigation. The study does not prove the following:
- Direct melanoma elimination: Although high nevus density is a known risk marker for cutaneous malignant melanoma, the trial measured the acquisition of benign nevi over 3 years, not the lifelong development of skin cancer itself.
- Universal applicability across all populations: The analysis focused exclusively on white children in grades 1 and 4 residing in Vancouver; nonwhite children were excluded from the final analytical cohort. Therefore, the numerical outcomes cannot be generalized to every skin phototype or climate.
- Absolute prevention: The intervention attenuated, rather than stopped, mole formation. Even within the sunscreen group, children still accumulated a median of 24 new nevi over the 3-year observation window.
Understanding Moles, Skin Risk, and Broader Protection
Because melanocytic nevi originate during childhood solar exposure, evaluating new spots remains a focal point for skin health. Understanding how moles form and change is central to long-term monitoring, as discussed in our review of melanotan, moles, and melanoma case reports. While sunscreen attenuates nevus development, complete sun safety relies on consistent habits rather than topical products alone.
As documented in the pediatric nevus trial published in JAMA, shielding young skin during extended periods outdoors reduces the cellular stimulus that triggers new moles. Anyone assessing changes in existing moles or considering photoprotection for their family should consult a board-certified dermatologist for tailored guidance. Readers seeking more details on filter classifications can also reference our guide on SPF and broad-spectrum sunscreen basics.
Sources
Published October 28, 2026. Sources are linked in the text. See our Medical Disclaimer.